相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
Landon Carter Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
Laura S. Graham et al.
PLOS ONE (2020)
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N. Graff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S. Antonarakis et al.
JCO PRECISION ONCOLOGY (2020)
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
Shuang G. Zhao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Sumanta K. Pal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D. Tucker et al.
CANCER MEDICINE (2019)
Immunotherapy for Prostate Cancer
Nicholas J. Venturini et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2019)
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer
Huijun Zhang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma of the bladder
Sonja Bergmann et al.
CANCER RESEARCH (2019)
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer
Verena Sailer et al.
JCO PRECISION ONCOLOGY (2019)
Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients
Daniel Worroll et al.
PHYSICAL BIOLOGY (2019)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Karim Boudadi et al.
Oncotarget (2018)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M. Ilie et al.
ANNALS OF ONCOLOGY (2018)
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Santosh Gupta et al.
CLINICAL CANCER RESEARCH (2017)
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
B. Benzon et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
Anna Katharina Seitz et al.
EUROPEAN UROLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
PROSTATE CANCER IN 2016 Improved outcomes and precision medicine come within reach
Cora N. Sternberg et al.
NATURE REVIEWS UROLOGY (2017)
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
Dorothea Sonja Schott et al.
ONCOTARGET (2017)
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Casey R. Ager et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Howard I. Scher et al.
CANCER RESEARCH (2017)
Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Deborah Mukherji et al.
CLINICAL GENITOURINARY CANCER (2016)
Development of a Novel c-MET-Based CTC Detection Platform
Tian Zhang et al.
MOLECULAR CANCER RESEARCH (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
Arun Satelli et al.
SCIENTIFIC REPORTS (2016)
Frequent expression of PD-L1 on circulating breast cancer cells
Martine Mazel et al.
MOLECULAR ONCOLOGY (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions
Michael B. Bernstein et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients
Yibin Kang et al.
CANCER CELL (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cancer Immunotherapy: Sipuleucel-T and Beyond
Aimee E. Hammerstrom et al.
PHARMACOTHERAPY (2011)
Tumor heterogeneity: Causes and consequences
Andriy Marusyk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases
Grant Chavin et al.
CLINICAL CANCER RESEARCH (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy
Timothy J. Roth et al.
CANCER RESEARCH (2007)
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R. Shaffer et al.
CLINICAL CANCER RESEARCH (2007)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
